Celyad Oncology SA (CYAD)
US1512052002 - ADR
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
MONT-SAINT-GUIBERT, Belgium, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today...
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
MONT-SAINT-GUIBERT, Belgium, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces...
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
Georges Rawadi was appointed Chief Executive Officer as from April 27, 2023Celyad Oncology has received approximately EUR 9.8m in private placement...
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
MONT-SAINT-GUIBERT, Belgium, Aug. 24, 2023 (GLOBE NEWSWIRE) -- regulated information / inside information - Celyad Oncology SA (“Celyad” or the...
Celyad Oncology announces receipt of Nasdaq delisting notice
Celyad Oncology announces receipt of Nasdaq delisting notice
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), is a biotechnology company...
Celyad plans to delist from Nasdaq amid cash woes
Celyad Oncology (CYAD) is delisting its American Depositary Shares (ADSs) from Nasdaq. Read more here
Celyad Oncology reports first quarter 2023 financial results and recent business highlights
Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq
Celyad Oncology reports first quarter 2023 financial results and recent business highlights
Presentation of updated data on our multiplex shRNA platform, which allows targeting of up to four genes simultaneouslyPublication of results from the...
Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq
MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company...
Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price
Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price
MONT-SAINT-GUIBERT, Belgium, April 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company...
Celyad Oncology announces receipt of Nasdaq notice
Celyad Oncology announces receipt of Nasdaq notice
MONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company...
Celyad Oncology appoints Georges Rawadi as its new CEO
Celyad Oncology appoints Georges Rawadi as its new CEO
MONT-SAINT-GUIBERT, Belgium, March 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company...
Celyad Oncology reports full year 2022 financial results and recent business highlights
Celyad Oncology reports full year 2022 financial results and recent business highlights
Starting in 2023, Celyad Oncology is now entirely focused on its new business strategy with one clear objective: help to overcome the current limitations...
Celyad Oncology to announce full year 2022 financial results and host conference call
Celyad Oncology to announce full year 2022 financial results and host conference call
MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're beginning the day with a look at the biggest pre-market stock movers traders need to know about for Wednesday morning!
Celyad stock slumps ~30% as board to put proposal to continue activities on vote
Celyad Oncology (CYAD) said it will recognize a non-cash impairment of its goodwill and intangible oncology assets and that its board plans to submit for a vote its business plan...
Celyad Oncology announces non-cash impairment
Celyad Oncology announces non-cash impairment
MONT-SAINT-GUIBERT, Belgium, March 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company...
REPEAT -- Celyad Oncology SA - Letter to Shareholders
Celyad Oncology SA - Letter to Shareholders
Celyad Oncology SA - Letter to Shareholders
MONT-SAINT-GUIBERT, Belgium, Feb. 28, 2023 (GLOBE NEWSWIRE) -- The following is a statement by Celyad Oncology: Dear Shareholder, 2022 has been a...